Alemtuzumab

Details

Files

Generic Name:

Alemtuzumab

Project Status:

Withdrawn

Therapeutic Area:

Multiple sclerosis, relapsing-remitting

Manufacturer:

Genzyme Canada, a Division of sanofi-aventis Canada Inc.

Call for patient/clinician input open:

September 30, 2013

Brand Name:

Lemtrada

Project Line:

Reimbursement Review

Project Number:

SR0355-000

Call for patient/clinician input closed:

October 23, 2013

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Multiple Sclerosis, relapsing

Last Updated : October 1, 2013